Artesunate rectal - Cipla/Medicines for Malaria Venture/Strides

Drug Profile

Artesunate rectal - Cipla/Medicines for Malaria Venture/Strides

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator World Health Organization
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Malaria

Most Recent Events

  • 01 Dec 2015 Cipla and Strides submit Artesunate rectal for pre-qualification review to the WHO (MMV pipeline - May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top